Investor Overview

Stock Information
Loading data...
Press Releases
May 20, 2022

Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced the pricing of its previously announced underwritten public offering of 22,665,000 shares of its common stock, 12,835,000...

May 19, 2022

Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu of common...

May 10, 2022

Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has selected Bora Pharmaceuticals Services Inc. (Bora) Canada as Evofem's new contract manufacturing organization (CMO). Bora will...

May 6, 2022

5.8% of Women in the AMPOWER Trial Experienced an On-Study Urinary Tract Infection Compared to 11% in the General Population The Post hoc Analysis will be Presented at the 2022 American College of...

May 5, 2022

Evofem Biosciences, Inc., (Nasdaq: EVFM) (the "Company") today announced that the Board and stockholders of the Company approved a 1-for-15 reverse stock split of the Company's common stock at the...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at  

The Company is evaluating Phexxi for two potential new indications: the prevention of urogenital chlamydia and gonorrhea in women. Top-line results are expected from its confirmatory Phase 3 clinical trial, EVOGUARD, in the second half of 2022. Positive outcomes could support submission to the FDA for these potential new indications in the first quarter of 2023, with an anticipated PDUFA date in the second half of 2023 due to the expedited review afforded by the Fast Track designations granted for these indications.

The addressable U.S. market opportunity for these current and investigational indications is estimated at $3.6 - $4.5 billion in aggregate.  

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. Discussions are underway with potential licensees for commercialization of Phexxi in multiple international markets.

Featured Event
Wednesday, May 4, 2022
04:30 pm - 05:15 pm EDT

Evofem discussed financial results and business highlights for Q1 2022 on May 4th. Access the replay through the webcast link at the left.

View All

Latest Financial Results

Q4 2021, Ended Dec 31, 2021

Earnings Release
Earnings Call
10-K Filing